Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP001271

Drug Information
NameVoriconazole    
SynonymsUNII-JFU09I87TR; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; AC1Q4O6I; MLS000759464; Vfend, Voriconazole; C07622; HMS2051N09; D00578; SMR000466350; Vfend; ZINC00014864; CHEBI:10023; TL8000858; MLS001424082; UK-109,496; C102790; Voriconazole [USAN:INN:BAN]; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; UK 109496; DB00582; 137234-62-9; Vfend (TN); AKOS005145705; S1442_Selleck; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VCZ; SAM001246664; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; Pfizer brand of voriconazole; UK-109496; AC1L2GHR; AC-823; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; 173967-54-9; LS-181799; UK 109,496; DRG-0301; VRC; MolPort-003-850-863; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-; Voriconazole (JAN/USAN/INN); Voriconazole; CHEMBL638; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-; CPD000466350; FT-0082604; Voriconazole in combination with MGCD290; CID71616    
Trade NameVFEND    
CompanyPfizer    
IndicationInvasive aspergillosisApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntifungal Agents    
CAS NumberCAS 137234-62-9
FormularC16H14F3N5O    
PubChem Compound IDCID 71616.    
PubChem Substance IDSID 9824.    
SuperDrug ATC IDJ02AC03;    
SuperDrug CAS ID137234629;    
TargetYeast Lanosterol 14-alpha demethylaseInhibitor[2]
Ref 1Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53. To Reference
Ref 2Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus. Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603. Epub 2008 Aug 11. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543